Key result
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists appear beneficial in animal models of myocarditis for reducing complications and downregulating autoimmune components.
Why the study?
The effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on myocarditis have been less studied in animal models of frank myocarditis compared to other heart failure and hypertension models.
Do angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists improve outcomes in animal models of myocarditis?
Do angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists improve outcomes in animal models of myocarditis?
ACE inhibitors and ARBs appear beneficial in experimental models of myocarditis by reducing complications and modulating autoimmune responses without exacerbating the initiating infection.
Answers are grounded in this paper and cite their sources.
Should not yet change myocarditis management; leaves open translation of animal benefits to human trials.
Myocarditis is a disease whose pathogenesis is not completely understood and whose prevalence is likely underestimated. Individuals afflicted with this condition may be treated with agents that relieve symptoms arising from inflammation and concurrent cellular damage. One class of drugs commonly used in the treatment of myocarditis includes the angiotensin converting enzyme inhibitors, such as captopril, enalapril and lisinopril, and the angiotensin Pi receptor antagonists, such as L-158,809 and losartan. The effects of these drugs on cardiomyopathy have been studied using a variety of animal models of heart failure and hypertension. However, less research has been done in the area of animal models of frank myocarditis. Here we review the use of angiotensin converting enzyme inhibitors and angiotensin Pi receptor antagonists in animal models of myocarditis. We extend the implications of that published work by correlation with results from studies of other disease models and in vitro experiments that highlight the immunomodulatory potential of these compounds. The literature strongly suggests that aggressive therapy employing angiotensin converting enzyme inhibition and/or blockade of angiotensin Pi receptors is beneficial. Treatment is useful not only for reducing complications associated with myocarditis, but also for downregulating the potential autoimmune component of disease without increasing the levels of the infectious agent that may initiate the myocarditis.
No takes yet. Share an insight, caveat, or question.
Godsel et al. (2003) conducted a review in Myocarditis. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists was evaluated. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists appear beneficial in animal models of myocarditis for reducing complications and downregulating autoimmune components.
Synapse has enriched 10 related papers. Consider them for comparative context: